WSLHD
Skip navigation
Please use this identifier to cite or link to this item: https://wslhd.intersearch.com.au/wslhdjspui/handle/1/8920
TitleDirect oral anticoagulants (DOACs) use for prolonged venous thromboembolism prophylaxis following surgery for gynaecological malignancies in Australia and New Zealand - A clinician survey
Authors: Boo, Marilyn;Simcock, B.;Sykes, P.;Brand, Alison H.
WSLHD Author: Boo, Marilyn;Brand, Alison H.
Issue Date: 2024
Citation: Australian & New Zealand Journal of Obstetrics & Gynaecology 64(1):36-41, 2024
Abstract: BACKGROUND: Current international guidelines recommend 28 days of enoxaparin as venous thromboembolism (VTE) prophylaxis after surgery for gynaecologic cancer. Direct oral anticoagulants (DOACs) have been investigated as an alternative to enoxaparin for post-operative VTE prophylaxis. High-quality evidence to demonstrate safety and efficacy is lacking. AIMS: We aim to investigate the current practice regarding VTE prophylaxis among gynaecological oncologists in Australia and New Zealand following laparotomy for gynaecological malignancy, in particular the use of DOACs for VTE prophylaxis. MATERIALS AND METHODS: Sixty-seven practising gynaecologic oncologists (GO) were identified through Royal Australia and New Zealand College of Obstetricians and Gynaecologists database and emailed online surveys that asked about VTE prophylaxis practice and views of DOACs in this setting. Data were then collected through Survey Monkey and evaluated.
RESULTS: The majority (77.1%) routinely prescribed 28 days of enoxaparin following laparotomy for gynaecological malignancies. In clinical circumstance such as laparoscopy for gynaecological malignancies and surgery for vulva malignancies, there was variation in thromboprophylaxis practices. No GO reported routine use of DOACs in any clinical circumstance. There were 56% of GOs who used a DOAC in their practice at some point. Barriers to routine use of DOACs in current practice included insufficient evidence (68%), issue with cost (40.4%) and concerns about safety (29.7%). CONCLUSIONS: Enoxaparin prescribed for 28 days remains the current clinical practice in preventing VTE following laparotomy for gynaecological malignancy. The main barrier to routine DOAC use as post-operative thromboprophylaxis is a lack of evidence which reflects the need for a larger prospective study. Copyright 2023 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
URI: https://wslhd.intersearch.com.au/wslhdjspui/handle/1/8920
DOI: https://dx.doi.org/10.1111/ajo.13737
Journal: Australian & New Zealand Journal of Obstetrics & Gynaecology
Type: Journal Article
Department: Gynaecology Oncology
Facility: Westmead
Keywords: Anticoagulants
Venous Thromboembolism
Enoxaparin
Genital Neoplasms, Female
New Zealand
Appears in Collections:Westmead Hospital 2019 - 2024

Files in This Item:
There are no files associated with this item.


Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.